Patients ( n = @ ) with cT @ tumors , or negative hormone-receptor status , or positive hormone-receptor and clinically node-positive disease received four times epirubicin/cyclophosphamide and were thereafter randomly assigned to four times docetaxel ( Taxotere ) , or four times docetaxel/capecitabine over @ weeks , or four times docetaxel followed by capecitabine over @ weeks .